In order to thrive, you need to have all of the tools at your fingertips, and that includes evidence-based therapies that go beyond conventional oncology.
Download our FREE PDF guide filled with evidence-based therapies that you can start today to manage your Pancreatic Cancer. Click the orange button to get your download now.
As a long term survivor of an incurable cancer, Multiple Myeloma, it became clear to me many years ago that many cancer patients need to venture beyond conventional oncology in order to heal themselves. Pancreatic cancer patients face the same challenges as MM patients face. Low-Dose Naltrexone (LDN) is one such therapy.
Whether you would like to both enhance the efficacy of conventional oncologic chemotherapy or reduce the toxicity of a conventional therapy, the important thing is that there are evidence-based integrative therapies.
While Low-Dose Naltrexone (LDN) is controversial as a cancer therapy, it is a therapy that needs to be learned about for those cancer patients who want to look beyond conventional cancer care. LDN is one of many evidence-based non-conventional cancer therapies. Further, I have remained in complete remission from my incurable cancer with the help of evidence-based, non-toxic therapies such as nutrition, supplementation, bone health, detoxification and mind-body therapies. Again, all supported by research.
For more information on other non-conventional and integrative therapies for your cancer, scroll down the page, post a question or a comment and I will reply ASAP.
“A panel of researchers and clinicians was convened by the National Cancer Institute (NCI) on March 19, 2012 for presentations and a roundtable discussion about “The State of the Science of Alpha-Lipoic Acid plus Low-Dose Naltrexone for the Treatment of Cancer.” The meeting was hosted by the NCI Office of Cancer Complementary and Alternative Medicine (OCCAM) and the Cancer Therapy Evaluation Program (CTEP), both part of the NCI Division of Cancer Treatment and Diagnosis (DCTD)…”
“The authors, in a previous article, described the long-term survival of a man with pancreatic cancer and metastases to the liver, treated with intravenous alpha-lipoic acid and oral low-dose naltrexone (ALA/N) without any adverse effects. He is alive and well 78 months after initial presentation. Three additional pancreatic cancer case studies are presented in this article. At the time of this writing, the first patient, GB, is alive and well 39 months after presenting with adenocarcinoma of the pancreas with metastases to the liver. The second patient, JK, who presented to the clinic with the same diagnosis was treated with the ALA/N protocol and after 5 months of therapy, PET scan demonstrated no evidence of disease. The third patient, RC, in addition to his pancreatic cancer with liver and retroperitoneal metastases, has a history of B-cell lymphoma and prostate adenocarcinoma. After 4 months of the ALA/N protocol his PET scan demonstrated no signs of cancer…”
“Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered the mechanism by which a low dose of the opioid antagonist naltrexone (LDN), an agent used clinically (off-label) to treat cancer and autoimmune diseases, exerts a profound inhibitory effect on cell proliferation…”
“The authors describe the long-term survival of a patient with pancreatic cancer without any toxic adverse effects. The treatment regimen includes the intravenous alpha-lipoic acid and low-dose naltrexone (ALA-N) protocol and a healthy lifestyle program.
The patient was told by a reputable university oncology center in October 2002 that there was little hope for his survival. Today, January 2006, however, he is back at work, free from symptoms, and without appreciable progression of his malignancy.
The integrative protocol described in this article may have the possibility of extending the life of a patient who would be customarily considered to be terminal. The authors believe that life scientists will one day develop a cure for metastatic pancreatic cancer, perhaps via gene therapy or another biological platform.
But until such protocols come to market, the ALA-N protocol should be studied and considered, given its lack of toxicity at levels reported. Several other patients are on this treatment protocol and appear to be doing well at this time.”